• InflaRx snags $55M for inflammatory, autoimmune trials fiercebiotech
    October 16, 2017
    InflaRx has raised $55 million (€47 million) in a new funding round. The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2a data.
PharmaSources Customer Service